Clinical Recommendations for Adenovirus Testing and Reporting of Children with Acute Hepatitis of Unknown Etiology
Click here to view the recording with the integrated audio transcript using the password below. external icon
“This content and conclusions are those of the author and presenter and do not necessarily represent the views of, nor should any endorsements be inferred by, the Centers for Disease Control and Prevention.”
The fully captioned video and edited transcript will be posted within the next few days.
This COCA Call will be held on Friday, March 27, 2020
The Centers for Disease Control and Prevention (CDC) is investigating a cluster of children identified with hepatitis and adenovirus infection. CDC has recommended that U.S. clinicians who encounter pediatric patients with hepatitis of unknown etiology to consider adenovirus testing and to report such cases to state public health authorities and CDC. While there have been case reports of hepatitis in immunocompromised children with adenovirus type 41 infection in the past, adenovirus type 41 is not known to be a cause of hepatitis in otherwise healthy children. More common causes for hepatitis have been ruled out. During this COCA Call, presenters will discuss the unknown etiology of patients under investigation, progress of the investigation, and how clinicians can continue to support these efforts through testing and reporting.
L. Amanda Ingram, MPH
Infectious Diseases & Outbreaks Division
Alabama Department of Public Health
Jacqueline Tate, PhD
Epidemiology Team Lead, Viral Gastroenteritis Branch
Division of Viral Diseases
National Center for Immunization and Respiratory Diseases
Centers for Disease Control and Prevention
Helena Gutierrez, MD
Medical Director, Pediatric Liver Transplant Program
Assistant Professor, Division of Pediatric Gastroenterology, Hepatology, and Nutrition
The University of Alabama at Birmingham
Elizabeth A. Moulton, MD, PhD
Assistant Professor of Pediatrics
Transplant Infectious Diseases
Baylor College of Medicine
Texas Children’s Hospital
Thursday, May 19, 2022,
2:00 PM – 3:00 PM ET
US: +1 669 254 5252
or +1 646 828 7666
or +1 669 216 1590
or +1 551 285 1373
International numbersexternal icon
US: +16692545252,,1611321885#,,,,*854934# or +16468287666,,1611321885#,,,,*854934#
Webinar ID: 161 132 1885Add to Calendar
Due to the high demand we anticipate for this COCA Call, we encourage participants to consider viewing on Facebook. To see the call live, please click on COCA’s Facebook Page.
Registration is not required.
Date: Thursday, May 19, 2022
Time: 2:00 PM – 3:00 PM ET
A few minutes before the webinar begins, please click the link below to join:
Webinar ID: 161 132 1885
Dial-in US: +1 669 254 5252 or +1 646 828 7666 or +1 669 216 1590 or +1 551 285 1373
One-tap mobile: US: +16692545252,,1611321885#,,,,*854934# or +16468287666,,1611321885#,,,,*854934#
International numbers available: https://www.zoomgov.com/u/aepTw4XmFyexternal icon
- Describe the current investigation of cases in Alabama and other U.S. states.
- Discuss the unknown etiology of cases as it relates to hepatitis and adenovirus type 41.
- Explain how clinicians can best support the investigation through testing and reporting cases in their states.
COCA Call Objectives
- Cite background information on the topic covered during the presentation.
- Discuss CDC’s role in the topic covered during the presentation.
- Describe the topic’s implications for clinicians.
- Discuss concerns and/or issues related to preparedness for and/or response to urgent public health threats.
- Promote health improvement, wellness, and disease prevention in cooperation with patients, communities, at-risk populations, and other members of an interprofessional team of healthcare providers.
To receive continuing education (CE) for WC4520-051922 – Clinician Outreach and Communication Activity (COCA) Calls/Webinars – Clinical Recommendations for Adenovirus Testing and Reporting of Children with Acute Hepatitis of Unknown Etiology, Thursday, May 19, 2022, please visit TCEO and follow these 9 Simple Steps by Monday, June 20, 2022.
To receive continuing education (CE) for WD4520-051922 – Clinician Outreach and Communication Activity (COCA) Calls/Webinars – Clinical Recommendations for Adenovirus Testing and Reporting of Children with Acute Hepatitis of Unknown Etiology, Thursday, May 19, 2022, (Web on Demand), please visit TCEO and follow these 9 Simple Steps between Tuesday, June 21, 2022, and Friday, June 21, 2024
In support of improving patient care, the Centers for Disease Control and Prevention is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CME: The Centers for Disease Control and Prevention designates this activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AAPA CME: The Centers for Disease Control and Prevention has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 12/13/2023. PAs should only claim credit commensurate with the extent of their participation
CNE: The Centers for Disease Control and Prevention designates this activity for 1 nursing contact hours.
CPE: The Centers for Disease Control and Prevention designated this (Knowledge-based) event for pharmacists to receive 0.1 CEUs in pharmacy education. The Universal Activity Number is JA4008229-0000-22-068-L04-P and enduring JA4008229-0000-22-069-H04-P.
Once credit is claimed, an unofficial statement of credit is immediately available on TCEOnline. Official credit will be uploaded within 60 days on the NABP/CPE Monitor.
CEU: The Centers for Disease Control and Prevention is authorized by IACET to offer 0.1 CEU’s for this program.
CECH: Sponsored by the Centers for Disease Control and Prevention, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designated for Certified Health Education Specialists (CHES®) and/or Master Certified Health Education Specialists (MCHES®) to receive up to 1.0 total Category I continuing education contact hours. Maximum advanced level continuing education contact hours available are 1. Continuing Competency credits available are 1. CDC provider number 98614.
AAVSB/RACE: This program was reviewed and approved by the AAVSB RACE program for 1.0 hours of continuing education. Participants should be aware that some boards have limitations on the number of hours accepted in certain categories and/or restrictions on certain methods of delivery of continuing education. Please contact the AAVSB RACE program at firstname.lastname@example.org if you have any comments/concerns regarding this program’s validity or relevancy to the veterinary profession.
For Certified Public Health Professionals (CPH): The Centers for Disease Control and Prevention is a pre-approved provider of Certified in Public Health (CPH) recertification credits and is authorized to offer 1 CPH recertification credits for this program.
DISCLOSURE: In compliance with continuing education requirements, all planners and presenters must disclose all financial relationships, in any amount, with ineligible companies over the previous 24 months as well as any use of unlabeled product(s) or products under investigational use.
CDC, our planners, and presenters wish to disclose they have no financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients, with the exception of Dr. Elizabeth Moulton who would like to disclose that she is a sub-investigator for SARS-CoV-2 pediatric vaccine trials with Pfizer and that funds went to institution; she would also like to disclose that she is the principal investigator for a pediatric Paxlovid trial with Pfizer. In addition, Dr. Luz Helena Gutierrez would like to disclose that she is on the advisory board for Albireo Pharmaceuticals.
All of the relevant financial relationships listed for these individuals have been mitigated.
Content will not include any discussion of the unlabeled use of a product or a product under investigational use with the exception of Dr. Elizabeth Moulton who may discuss off label use of cidofovir for adenovirus treatment.
CDC did not accept financial or in-kind support from ineligible companies for this continuing education activity.
- Physician Assistants
- Health Educators
- Other Clinicians
- Contact Information:email@example.com
- Support/Funding:Centers for Disease Control and Prevention, Emergency Risk Communication Branch
- Method of Participation:You may participate in the educational activity by viewing the program information above.